FDA clears Phase 2 trial testing C5 inhibitor IM-101 in MG patients
Investigational therapy's effectiveness at easing symptoms to be evaluated
The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 2 clinical trial testing IM-101, ImmunAbs’ investigational therapy for myasthenia gravis (MG).
The multicenter, placebo-controlled trial is expected to enroll up to 90 people with MG who will receive IM-101 or a placebo once monthly. The trial will evaluate the treatment’s safety and effectiveness at easing MG symptoms.
“This … approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders,” Dongjo Kim, PhD, ImmunAbs’ CEO, said in a company press release. “We believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.”
IM-101 showed higher C5 inhibitory activity in preclinical studies
MG is an autoimmune disease characterized by muscle weakness and fatigue. It is caused by self-reactive antibodies that attack proteins involved in nerve-muscle communication and are needed to coordinate voluntary movements.
A growing body of evidence suggests that the activation of the complement system, a group of immune proteins that normally help defend the body against infections, also plays a role in driving MG.
Several complement inhibitor therapies that work to block complement activation have been approved to treat MG, such as Soliris (eculizumab), Ultomiris (ravulizumab-cwvz), and Zilbrysq (zilucoplan). All of them work by targeting a complement protein called C5. While existing C5 inhibitors have improved patient outcomes, some MG patients still experience residual disease activity due to incomplete complement inhibition, according to ImmunAbs.
IM-101 is a humanized antibody-based therapy that also targets the C5 protein and inhibits complement activation. In preclinical studies, it was found to have a higher C5 inhibitory activity compared with existing C5 antibody therapies.
A recently concluded Phase 1 clinical trial involving healthy volunteers who were given single-ascending doses of IM-101, or a placebo, demonstrated the treatment had a favorable safety profile and was well tolerated at all tested doses. No dose-limiting toxicity or severe adverse events were reported.
Additionally, IM-101 was shown to reduce C5 protein levels in the blood of the trial participants, supporting its efficacy in reducing the activity of the complement system in humans.
About the Author
